PAN submits letter in support of the NIH Clinical Integrity Act
Information about this website: Following the March 2026 merger of Patient Advocate Foundation and the PAN Foundation, this website is now a part of Patient Advocate Foundation and remains active during our website transition.
Where to find information during our transition:
- About the merged organization: uniting.patientadvocate.org
- Financial assistance: totalassist.org
- Additional direct patient services and resources: patientadvocate.org
- Education: panfoundation.org and education.patientadvocate.org
- Clinical trials education: clinicaltrials.panfoundation.org
- Advocacy: npaf.org
- Research: patientinsightinstitute.org
The PAN Foundation submitted a letter to Senate and House representative sponsors in support of their reintroduction of the NIH Clinical Integrity Act. A bipartisan and bicameral bill, the NIH Clinical Integrity Act seeks to bolster participation in NIH funded clinical trials to ensure that treatments and interventions are safe and effective for all patient populations. Reflecting America’s diversity in clinical trial participation is important as people may experience the same disease differently. Clinical trials should include people with a variety of lived experiences and living conditions, as well as characteristics like race and ethnicity, age, sex, and sexual orientation, so that all communities can benefit from scientific advances. The NIH Clinical Integrity Act importantly seeks to increase such populations in NIH clinical trials.